EA201401352A1 - Вакцина против вируса шмалленберга (sbv), способы ее получения и применения - Google Patents

Вакцина против вируса шмалленберга (sbv), способы ее получения и применения

Info

Publication number
EA201401352A1
EA201401352A1 EA201401352A EA201401352A EA201401352A1 EA 201401352 A1 EA201401352 A1 EA 201401352A1 EA 201401352 A EA201401352 A EA 201401352A EA 201401352 A EA201401352 A EA 201401352A EA 201401352 A1 EA201401352 A1 EA 201401352A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sbv
virus
shmallberg
methods
vaccine against
Prior art date
Application number
EA201401352A
Other languages
English (en)
Other versions
EA034543B1 (ru
Inventor
Велько Николин
Конрад Штадлер
Аксель Лишевски
Александер Брикс
Джеффри П. Ниттел
Катарина Хедвиг Тёпфер
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA201401352A1 publication Critical patent/EA201401352A1/ru
Publication of EA034543B1 publication Critical patent/EA034543B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12061—Methods of inactivation or attenuation
    • C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к области вакцин и лекарственных средств для профилактики и лечения инфекционных вирусных заболеваний у жвачных животных. В заявке описан инактивированный вирус Шмалленберга (SBV), который можно применять в качестве вакцины или лекарственного средства для предупреждения или лечения виремии, передачи вируса и клинических симптомов, прежде всего пороков развития у новорожденных жвачных животных, таких как крупный рогатый скот, овцы и козы, индуцированных SBV.
EA201401352A 2012-06-01 2013-05-29 Иммуногенная композиция (вакцина) против вируса шмалленберга (sbv), способ ее получения и способ индукции иммунного ответа против sbv EA034543B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170631 2012-06-01
EP13157875 2013-03-05
PCT/US2013/043146 WO2013181270A1 (en) 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Publications (2)

Publication Number Publication Date
EA201401352A1 true EA201401352A1 (ru) 2015-05-29
EA034543B1 EA034543B1 (ru) 2020-02-19

Family

ID=48607368

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401352A EA034543B1 (ru) 2012-06-01 2013-05-29 Иммуногенная композиция (вакцина) против вируса шмалленберга (sbv), способ ее получения и способ индукции иммунного ответа против sbv

Country Status (17)

Country Link
US (2) US9370562B2 (ru)
EP (1) EP2855513B1 (ru)
JP (1) JP6250649B2 (ru)
CN (1) CN104350066B (ru)
AR (1) AR091240A1 (ru)
AU (1) AU2013267453C1 (ru)
BR (1) BR112014029515A2 (ru)
CA (1) CA2872961A1 (ru)
DK (1) DK2855513T3 (ru)
EA (1) EA034543B1 (ru)
ES (1) ES2617351T3 (ru)
IN (1) IN2014DN08927A (ru)
MX (1) MX363044B (ru)
PL (1) PL2855513T3 (ru)
SG (1) SG11201407619SA (ru)
UY (1) UY34840A (ru)
WO (1) WO2013181270A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241960B2 (en) 2012-06-01 2016-01-26 Boehringer Ingelheim Vetmedica Gmbh Infectious Schmallenberg virus from cloned CDNAS and uses thereof
EA034543B1 (ru) 2012-06-01 2020-02-19 Бёрингер Ингельхайм Ветмедика Гмбх Иммуногенная композиция (вакцина) против вируса шмалленберга (sbv), способ ее получения и способ индукции иммунного ответа против sbv
HK1216006A1 (zh) * 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
CN104232587B (zh) * 2014-09-02 2016-08-17 中国检验检疫科学研究院 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用
CN120758460A (zh) * 2025-07-04 2025-10-10 中国兽医药品监察所 一种施马伦贝格病毒的假病毒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811736B2 (ja) * 1986-08-07 1996-02-07 財団法人化学及血清療法研究所 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
WO2008112707A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
US9241960B2 (en) 2012-06-01 2016-01-26 Boehringer Ingelheim Vetmedica Gmbh Infectious Schmallenberg virus from cloned CDNAS and uses thereof
EA034543B1 (ru) 2012-06-01 2020-02-19 Бёрингер Ингельхайм Ветмедика Гмбх Иммуногенная композиция (вакцина) против вируса шмалленберга (sbv), способ ее получения и способ индукции иммунного ответа против sbv

Also Published As

Publication number Publication date
AR091240A1 (es) 2015-01-21
EA034543B1 (ru) 2020-02-19
MX2014014521A (es) 2015-02-24
AU2013267453C1 (en) 2017-08-10
JP6250649B2 (ja) 2017-12-20
IN2014DN08927A (ru) 2015-05-22
JP2015519367A (ja) 2015-07-09
BR112014029515A2 (pt) 2017-07-25
CN104350066A (zh) 2015-02-11
SG11201407619SA (en) 2014-12-30
CN104350066B (zh) 2018-06-19
AU2013267453B2 (en) 2017-04-06
EP2855513A1 (en) 2015-04-08
ES2617351T3 (es) 2017-06-16
US20130323277A1 (en) 2013-12-05
US20160250317A1 (en) 2016-09-01
DK2855513T3 (en) 2017-03-13
EP2855513B1 (en) 2016-12-07
US9370562B2 (en) 2016-06-21
CA2872961A1 (en) 2013-12-05
US9872897B2 (en) 2018-01-23
WO2013181270A1 (en) 2013-12-05
PL2855513T3 (pl) 2017-05-31
MX363044B (es) 2019-03-06
UY34840A (es) 2013-12-31
AU2013267453A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
MX387277B (es) Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201491889A1 (ru) Соединения и способы для противовирусной терапии
EA201270063A1 (ru) Рекомбинантные антигены pcb
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
MX2018013782A (es) Antigenos y vacunas dirigidos contra enterovirus humanos.
PH12015502230B1 (en) Novel viral replication inhibitors
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201401352A1 (ru) Вакцина против вируса шмалленберга (sbv), способы ее получения и применения
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX389474B (es) Dimetilfumarato y regimenes de vacunacion.
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
UY34841A (es) VIRUS INFECCIOSO DE SCHMALLENBERG DE cADN CLONADOS Y SUS USOS
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
PH12014501688A1 (en) Influenza c virus and vaccine
EA201390452A1 (ru) Вакцина
PH12017500928A1 (en) A rabies composition comprising pika adjuvant
EA201990314A1 (ru) Новые ингибиторы вирусной репликации

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM